文献速递其他结缔组织病

皮肌炎患者血清白细胞介素-34水平:抗MDA5抗体相关间质性肺病的潜在生物标志物

Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究采用ELISA法检测56例皮肌炎患者和14例年龄、性别匹配的健康对照的血清IL-34水平,并分析其与临床参数的相关性,另对7例抗MDA5抗体阳性皮肌炎患者检测治疗前后血清IL-34水平。结果显示皮肌炎患者血清IL-34水平显著升高,尤其抗MDA5抗体阳性者,且与铁蛋白和抗MDA5抗体水平正相关,联合免疫抑制治疗后随二者下降。作者认为IL-34可能参与抗MDA5抗体阳性皮肌炎中快速进展型间质性肺病的发生,血清IL-34水平可作为该临床实体的潜在生物标志物。

要点

  • 皮肌炎患者血清IL-34水平较健康对照显著升高,抗MDA5抗体阳性者尤为明显。
  • 抗MDA5抗体阳性皮肌炎中,血清IL-34与铁蛋白及抗MDA5抗体水平正相关。
  • 联合免疫抑制治疗后,血清IL-34随铁蛋白和抗MDA5抗体一同下降。

核心结论

  • 这些数据提示IL-34可能参与抗MDA5抗体阳性皮肌炎中快速进展型间质性肺病的发生。
  • 血清IL-34水平可作为该临床实体中快速进展型间质性肺病的潜在生物标志物。

研究设计与样本

  • 研究采用ELISA法检测56例皮肌炎患者和14例年龄、性别匹配的健康对照的血清IL-34水平,并分析其与临床参数的相关性。
  • 另使用7例抗MDA5抗体阳性皮肌炎患者的血清样本检测治疗前后血清IL-34水平。

主要发现

  • 与健康对照相比,皮肌炎患者血清IL-34水平显著升高,尤其抗MDA5抗体阳性者。
  • 在抗MDA5抗体阳性皮肌炎患者中,血清IL-34水平与血清铁蛋白和抗MDA5抗体水平正相关,后者为已知的快速进展型间质性肺病生物标志物。
  • 联合免疫抑制治疗后,血清IL-34水平随铁蛋白和抗MDA5抗体下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: IL-34 is a haematopoietic cytokine that promotes macrophage activation. Macrophage activation in interstitial lung disease (ILD) in patients with DM, especially in those with anti-melanoma differentiation-associated gene 5 (MDA5) antibody suggests the involvement of IL-34 in the disease. However, the association between IL-34 and DM is unknown. In this study, we aimed to determine serum IL-34 levels in DM patients and evaluate their association with DM-ILD. METHODS: We measured serum IL-34 levels in 56 DM patients and 14 age- and sex- matched healthy controls by ELISA, and examined their correlation with clinical parameters. In addition, pre- and post-treatment serum IL-34 levels were examined using serum samples from 7 anti-MDA5 antibody-positive DM patients. RESULTS: Serum IL-34 levels were significantly elevated in DM patients, especially in those with anti-MDA5 antibody, compared with healthy controls. In anti-MDA5-antibody-positive DM patients, serum IL-34 levels positively correlated with serum levels of ferritin and anti-MDA5 antibody, which are known biomarkers for rapidly progressive (RP)-ILD. Following combined immunosuppressive therapy, serum IL-34 levels decreased along with ferritin and anti-MDA5 antibody. CONCLUSION: These data suggest that IL-34 may be involved in the development of RP-ILD in anti-MDA5 antibody-positive DM. Serum IL-34 levels can serve as a potential biomarker for RP-ILD in this clinical entity.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kuzumi A, Fukasawa T, Yamashita T, et al. Serum interleukin-34 levels in dermatomyositis: a potential biomarker for anti-MDA5-antibody-associated interstitial lung disease. Rheumatology (Oxford). 2025. PMID: 38830088. doi:10.1093/rheumatology/keae313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。